The acceleration addresses a growing pressure on sponsors and contract research organizations to shorten startup windows while managing increasingly intricate protocols. These new capabilities handle complex trial designs, including adaptive dose finding, basket studies, and platform trials, without sacrificing the technical rigor required for regulatory compliance.
Sanjiv Waghmare, chief product officer at Signant, stated that the innovation provides sponsors with both speed and reliability. The company is applying AI to its existing implementation models, allowing teams to execute mid-study amendments up to 60 percent faster. For pharmaceutical companies, this translates to routine operational changes being finalized in as little as one week, providing greater predictability throughout the lifecycle of a study.
Comments (0)
No comments yet. Be the first!